Abstract
The tumor necrosis factor (TNF) gene is an immediate early gene, rapidly transcribed in a variety of cell types following exposure to a broad range of pathogens and signals of inflammation and stress. Regulation of TNF gene expression at the transcriptional level is cell type- and stimulus-specific, involving epigenetic mechanisms or miRNAs. A better knowledge of the molecular mechanisms that control TNF gene regulation and TNF signalling will provide deeper understanding of the initiation and development of apoptotic and inflammatory processes triggered by TNF cytokine in the gut. The described efforts to embed TNF in clinical treatment regiments reflect its attractive effectiveness in killing tumor cells. Whether the described strategies will achieve the success of incorporating TNF in lower gastrointestinal tract therapy for inflammatory diseases and cancer remains to be determined.
Keywords: TNF signalling, apoptosis, colorectal tumor cells, radiotherapy, intestinal epithelial cells, immune cells, tumor necrosis factor (TNF), cancer, Apoptosis, cytotoxic therapy
Current Pharmaceutical Biotechnology
Title:Apoptosis Signalling Activated by TNF in the Lower Gastrointestinal Tract-Review
Volume: 13 Issue: 11
Author(s): Natalya Benderska, Saritha Chakilam, Manuela Hugle, Jelena Ivanovska, Muktheshwar Gandesiri, Jan Schulze-Luhrmann, Khuloud Bajbouj, Ronald Croner and Regine Schneider-Stock
Affiliation:
Keywords: TNF signalling, apoptosis, colorectal tumor cells, radiotherapy, intestinal epithelial cells, immune cells, tumor necrosis factor (TNF), cancer, Apoptosis, cytotoxic therapy
Abstract: The tumor necrosis factor (TNF) gene is an immediate early gene, rapidly transcribed in a variety of cell types following exposure to a broad range of pathogens and signals of inflammation and stress. Regulation of TNF gene expression at the transcriptional level is cell type- and stimulus-specific, involving epigenetic mechanisms or miRNAs. A better knowledge of the molecular mechanisms that control TNF gene regulation and TNF signalling will provide deeper understanding of the initiation and development of apoptotic and inflammatory processes triggered by TNF cytokine in the gut. The described efforts to embed TNF in clinical treatment regiments reflect its attractive effectiveness in killing tumor cells. Whether the described strategies will achieve the success of incorporating TNF in lower gastrointestinal tract therapy for inflammatory diseases and cancer remains to be determined.
Export Options
About this article
Cite this article as:
Benderska Natalya, Chakilam Saritha, Hugle Manuela, Ivanovska Jelena, Gandesiri Muktheshwar, Schulze-Luhrmann Jan, Bajbouj Khuloud, Croner Ronald and Schneider-Stock Regine, Apoptosis Signalling Activated by TNF in the Lower Gastrointestinal Tract-Review, Current Pharmaceutical Biotechnology 2012; 13 (11) . https://dx.doi.org/10.2174/138920112802501971
DOI https://dx.doi.org/10.2174/138920112802501971 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
siRNA Therapy, Challenges and Underlying Perspectives of Dendrimer as Delivery Vector
Current Pharmaceutical Design Synthesis of Aza-BODIPY Boron Difluoride PDT Agents to Promote Apoptosis in HeLa Cells
Letters in Organic Chemistry IgG4-Related Disease (IgG4+MOLPS) – Diagnostic Criteria and Diagnostic Problems
Current Immunology Reviews (Discontinued) Subject Index to Volume 3
Current Drug Targets - Cardiovascular & Hematological Disorders Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets Nucleic Acid Aptamers Against Protein Kinases
Current Medicinal Chemistry The Controlled Release of Drugs and Bioactive Compounds from Mesoporous Silica Nanoparticles
Current Drug Delivery Cellular Targets and Mechanisms in the Cytotoxic Action of Non-biodegradable Engineered Nanoparticles
Current Drug Metabolism Molecular Approach to Targeted Therapy for Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Sphingolipid Modulation: A Strategy for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Treatment of Squamous Cell Carcinoma of the Head and Neck in the Metastatic and Refractory Settings: Advances in Chemotherapy and the Emergence of Small Molecule Epidermal Growth Factor Receptor Kinase Inhibitors
Current Cancer Drug Targets Meet Our Editorial Board Member
Current Drug Therapy Astatine Radiopharmaceuticals: Prospects and Problems
Current Radiopharmaceuticals Endometriosis and Gynecological Cancer
Current Women`s Health Reviews Applications of Polymeric Nanocapsules in Field of Drug Delivery Systems
Current Drug Discovery Technologies ROS1 Kinase Inhibitors for Molecular-Targeted Therapies
Current Medicinal Chemistry Developments in Targeted Therapy of Advanced Gastrointestinal Stromal Tumors
Recent Patents on Anti-Cancer Drug Discovery Oncogene-Blocking Therapies: New Insights from Conditional Mouse Tumor Models
Current Cancer Drug Targets Emerging Immunotargets in Bladder Cancer
Current Drug Targets Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets
Current Enzyme Inhibition